5 Focus Areas for the C-Suite
[Editor’s Note:
Part I appeared
in
the
November/December
issue
.]
In
my
old
U.S.
FDA
role,
I
would
see
companies
terminate
multiple
quality
and
manufacturing
heads
shortly
after
receiving
a
warning
letter
and
profess
this
action
a
big
part
of
their
overall
remediation
solution.
But
the
CEO
always
remained
unchanged.
Why?
While
some
of
the
terminations
may
have
truly
been
warranted,
I
find
it
hard
to
believe
that
this
was
the
case
in
every
organization,
especially
since
the
CEO
and
his
C-suite
reports
were
never
touched.